WEKO3
アイテム
{"_buckets": {"deposit": "dc3422d4-072f-4318-9c67-30fef60dec47"}, "_deposit": {"created_by": 3, "id": "3773", "owners": [3], "pid": {"revision_id": 0, "type": "depid", "value": "3773"}, "status": "published"}, "_oai": {"id": "oai:hirosaki.repo.nii.ac.jp:00003773", "sets": ["654"]}, "author_link": ["13751", "13746", "13771", "13743", "13758", "13755", "13747", "13764", "13765", "13741", "13742", "13761", "11731", "13753", "13745", "13744", "13770", "13748", "13768", "13754", "13769", "13759", "13767", "13766", "13750", "13752", "13757", "13756", "13762", "13772", "13749", "13760"], "item_3_biblio_info_8": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2013-04-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "Supplement", "bibliographicPageEnd": "S27", "bibliographicPageStart": "S19", "bibliographicVolumeNumber": "64", "bibliographic_titles": [{"bibliographic_title": "弘前医学"}]}]}, "item_3_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Since January 2011, we have started to a personalized medicine for controlled-release tacrolimus, once-daily oral formulation of tacrolimus, based on the CYP3A5 polymorphisms. Tacrolimus has a narrow therapeutic range, and its pharmacokinetics differs greatly among individuals. Many factors may affect the pharmacokinetics of tacrolimus, including CYP3A5 genotypes. Patients with CYP3A5*1 allele( CYP3A5 expressers) require a higher daily tacrolimus dose than those with CYP3A5*3/*3 genotype (non-expressers) in order to maintain the target trough level. Recently, we investigated the increase in renal cortical interstitial fibrosis (IF) from 0-hour to 1-year posttransplantation using an automated digital analysis of biopsy sections and assessed the relative risk of developing IF based on clinical characteristics, laboratory data, tacrolimus-based immunosuppressive regimens, and the CYP3A5 polymorphism. In a multivariate analysis, CYP3A5 non-expression correlated with the development of IF. The mean tacrolimus trough concentrations in the early stages after transplantation were unexpectedly higher among non-expressers than CYP3A5 expressers, despite therapeutic drug monitoring. This unexpectedly high tacrolimus levels in non-expressers might influence the development of IF.\n Before staring the personalize medicine for controlled-release tacrolimus, we analyzed circadian pharmacokinetics and pharmacogenetics of twice daily tacrolimus, and its association with transplant outcome. We briefly reviewed our clinical research into tacrolimus.", "subitem_description_type": "Abstract"}]}, "item_3_description_7": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "弘前医学. 64(Suppl.), 2013, p.S19-27", "subitem_description_type": "Other"}]}, "item_3_full_name_2": {"attribute_name": "著者(ヨミ)", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "13757", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "サイトウ, シゲル"}]}, {"nameIdentifiers": [{"nameIdentifier": "13758", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "サイトウ, ミツル"}]}, {"nameIdentifiers": [{"nameIdentifier": "13759", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "ヌマクラ, カズユキ"}]}, {"nameIdentifiers": [{"nameIdentifier": "13760", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "ミウラ, ヨシオ"}]}, {"nameIdentifiers": [{"nameIdentifier": "13761", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "イノウエ, タカミツ"}]}, {"nameIdentifiers": [{"nameIdentifier": "13762", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "マイタ, シンヤ"}]}, {"nameIdentifiers": [{"nameIdentifier": "11731", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "セイノ, ヒロコ"}]}, {"nameIdentifiers": [{"nameIdentifier": "13764", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "ツルタ, ヒロシ"}]}, {"nameIdentifiers": [{"nameIdentifier": "13765", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "ナリタ, シンタロウ"}]}, {"nameIdentifiers": [{"nameIdentifier": "13766", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "ホリカワ, ヨウヘイ"}]}, {"nameIdentifiers": [{"nameIdentifier": "13767", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "ツチヤ, ノリヒコ"}]}, {"nameIdentifiers": [{"nameIdentifier": "13768", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "ハブチ, トモノリ"}]}, {"nameIdentifiers": [{"nameIdentifier": "13769", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "ミトベ, ヨウコ"}]}, {"nameIdentifiers": [{"nameIdentifier": "13770", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "コマツダ, アツシ"}]}, {"nameIdentifiers": [{"nameIdentifier": "13771", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "カガヤ, ヒデアキ"}]}, {"nameIdentifiers": [{"nameIdentifier": "13772", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "ミウラ, マサトモ"}]}]}, "item_3_publisher_35": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "弘前大学大学院医学研究科・弘前医学会"}]}, "item_3_radio_42": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"subitem_radio_item": "Article"}]}, "item_3_source_id_11": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00211444", "subitem_source_identifier_type": "NCID"}]}, "item_3_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0439-1721", "subitem_source_identifier_type": "ISSN"}]}, "item_3_subject_19": {"attribute_name": "日本十進分類法", "attribute_value_mlt": [{"subitem_subject": "490", "subitem_subject_scheme": "NDC"}]}, "item_3_subject_23": {"attribute_name": "NIIサブジェクト", "attribute_value_mlt": [{"subitem_subject": "医学", "subitem_subject_scheme": "Other"}]}, "item_3_text_4": {"attribute_name": "著者所属", "attribute_value_mlt": [{"subitem_text_value": "Department of Urology, Replacement Therapeutic Science, Akita University School of Medicine"}, {"subitem_text_value": "Division of Renal, Replacement Therapeutic Science, Akita University School of Medicine"}, {"subitem_text_value": "Department of Nephrology and Rheumatology, Akita University School of Medicine"}, {"subitem_text_value": "Department of Pharmacy, Akita University Hospital"}]}, "item_3_version_type_18": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Satoh, Shigeru"}], "nameIdentifiers": [{"nameIdentifier": "13741", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Saito, Mitsuru"}], "nameIdentifiers": [{"nameIdentifier": "13742", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Numakura, Kazuyuki"}], "nameIdentifiers": [{"nameIdentifier": "13743", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miura, Yoshio"}], "nameIdentifiers": [{"nameIdentifier": "13744", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Inoue, Takamitsu"}], "nameIdentifiers": [{"nameIdentifier": "13745", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Maita, Shinya"}], "nameIdentifiers": [{"nameIdentifier": "13746", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Obara, Takashi"}], "nameIdentifiers": [{"nameIdentifier": "13747", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsuruta, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "13748", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Narita, Shintaro"}], "nameIdentifiers": [{"nameIdentifier": "13749", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Horikawa, Yohei"}], "nameIdentifiers": [{"nameIdentifier": "13750", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsuchiya, Norihiko"}], "nameIdentifiers": [{"nameIdentifier": "13751", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Habuchi, Tomonori"}], "nameIdentifiers": [{"nameIdentifier": "13752", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mitobe, Yoko"}], "nameIdentifiers": [{"nameIdentifier": "13753", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Komatsuda, Atsushi"}], "nameIdentifiers": [{"nameIdentifier": "13754", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kagaya, Hideaki"}], "nameIdentifiers": [{"nameIdentifier": "13755", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miura, Masatomo"}], "nameIdentifiers": [{"nameIdentifier": "13756", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-03-13"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "HirosakiMedJ_64_S19.pdf", "filesize": [{"value": "284.2 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 284200.0, "url": {"label": "HirosakiMedJ_64_S19.pdf", "url": "https://hirosaki.repo.nii.ac.jp/record/3773/files/HirosakiMedJ_64_S19.pdf"}, "version_id": "3885ed40-a818-4569-87a5-951e7bf592bb"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "tacrolimus", "subitem_subject_scheme": "Other"}, {"subitem_subject": "CYP3A5 polymorphism", "subitem_subject_scheme": "Other"}, {"subitem_subject": "pharmacokinetics", "subitem_subject_scheme": "Other"}, {"subitem_subject": "circadian exposure", "subitem_subject_scheme": "Other"}, {"subitem_subject": "interstitial fibrosis", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Pharmacogenetics and Circadian exposure of Tacrolimus and Its Impact on the renal Transplant Outcome: A Way to a Personalized Medicine for Tacrolimus", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Pharmacogenetics and Circadian exposure of Tacrolimus and Its Impact on the renal Transplant Outcome: A Way to a Personalized Medicine for Tacrolimus"}]}, "item_type_id": "3", "owner": "3", "path": ["654"], "permalink_uri": "http://hdl.handle.net/10129/4863", "pubdate": {"attribute_name": "公開日", "attribute_value": "2013-04-30"}, "publish_date": "2013-04-30", "publish_status": "0", "recid": "3773", "relation": {}, "relation_version_is_last": true, "title": ["Pharmacogenetics and Circadian exposure of Tacrolimus and Its Impact on the renal Transplant Outcome: A Way to a Personalized Medicine for Tacrolimus"], "weko_shared_id": 3}
Pharmacogenetics and Circadian exposure of Tacrolimus and Its Impact on the renal Transplant Outcome: A Way to a Personalized Medicine for Tacrolimus
http://hdl.handle.net/10129/4863
http://hdl.handle.net/10129/48631fc22165-4dc0-4ba7-9d84-dcc1e4faaea6
名前 / ファイル | ライセンス | アクション |
---|---|---|
HirosakiMedJ_64_S19.pdf (284.2 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2013-04-30 | |||||
タイトル | ||||||
タイトル | Pharmacogenetics and Circadian exposure of Tacrolimus and Its Impact on the renal Transplant Outcome: A Way to a Personalized Medicine for Tacrolimus | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | tacrolimus | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | CYP3A5 polymorphism | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | pharmacokinetics | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | circadian exposure | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | interstitial fibrosis | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Satoh, Shigeru
× Satoh, Shigeru× Saito, Mitsuru× Numakura, Kazuyuki× Miura, Yoshio× Inoue, Takamitsu× Maita, Shinya× Obara, Takashi× Tsuruta, Hiroshi× Narita, Shintaro× Horikawa, Yohei× Tsuchiya, Norihiko× Habuchi, Tomonori× Mitobe, Yoko× Komatsuda, Atsushi× Kagaya, Hideaki× Miura, Masatomo |
|||||
著者(ヨミ) | ||||||
姓名 | サイトウ, シゲル | |||||
著者(ヨミ) | ||||||
姓名 | サイトウ, ミツル | |||||
著者(ヨミ) | ||||||
姓名 | ヌマクラ, カズユキ | |||||
著者(ヨミ) | ||||||
姓名 | ミウラ, ヨシオ | |||||
著者(ヨミ) | ||||||
姓名 | イノウエ, タカミツ | |||||
著者(ヨミ) | ||||||
姓名 | マイタ, シンヤ | |||||
著者(ヨミ) | ||||||
姓名 | セイノ, ヒロコ | |||||
著者(ヨミ) | ||||||
姓名 | ツルタ, ヒロシ | |||||
著者(ヨミ) | ||||||
姓名 | ナリタ, シンタロウ | |||||
著者(ヨミ) | ||||||
姓名 | ホリカワ, ヨウヘイ | |||||
著者(ヨミ) | ||||||
姓名 | ツチヤ, ノリヒコ | |||||
著者(ヨミ) | ||||||
姓名 | ハブチ, トモノリ | |||||
著者(ヨミ) | ||||||
姓名 | ミトベ, ヨウコ | |||||
著者(ヨミ) | ||||||
姓名 | コマツダ, アツシ | |||||
著者(ヨミ) | ||||||
姓名 | カガヤ, ヒデアキ | |||||
著者(ヨミ) | ||||||
姓名 | ミウラ, マサトモ | |||||
著者所属 | ||||||
Department of Urology, Replacement Therapeutic Science, Akita University School of Medicine | ||||||
著者所属 | ||||||
Division of Renal, Replacement Therapeutic Science, Akita University School of Medicine | ||||||
著者所属 | ||||||
Department of Nephrology and Rheumatology, Akita University School of Medicine | ||||||
著者所属 | ||||||
Department of Pharmacy, Akita University Hospital | ||||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Since January 2011, we have started to a personalized medicine for controlled-release tacrolimus, once-daily oral formulation of tacrolimus, based on the CYP3A5 polymorphisms. Tacrolimus has a narrow therapeutic range, and its pharmacokinetics differs greatly among individuals. Many factors may affect the pharmacokinetics of tacrolimus, including CYP3A5 genotypes. Patients with CYP3A5*1 allele( CYP3A5 expressers) require a higher daily tacrolimus dose than those with CYP3A5*3/*3 genotype (non-expressers) in order to maintain the target trough level. Recently, we investigated the increase in renal cortical interstitial fibrosis (IF) from 0-hour to 1-year posttransplantation using an automated digital analysis of biopsy sections and assessed the relative risk of developing IF based on clinical characteristics, laboratory data, tacrolimus-based immunosuppressive regimens, and the CYP3A5 polymorphism. In a multivariate analysis, CYP3A5 non-expression correlated with the development of IF. The mean tacrolimus trough concentrations in the early stages after transplantation were unexpectedly higher among non-expressers than CYP3A5 expressers, despite therapeutic drug monitoring. This unexpectedly high tacrolimus levels in non-expressers might influence the development of IF. Before staring the personalize medicine for controlled-release tacrolimus, we analyzed circadian pharmacokinetics and pharmacogenetics of twice daily tacrolimus, and its association with transplant outcome. We briefly reviewed our clinical research into tacrolimus. |
|||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 弘前医学. 64(Suppl.), 2013, p.S19-27 | |||||
書誌情報 |
弘前医学 巻 64, 号 Supplement, p. S19-S27, 発行日 2013-04-02 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0439-1721 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AN00211444 | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
日本十進分類法 | ||||||
主題Scheme | NDC | |||||
主題 | 490 | |||||
NIIサブジェクト | ||||||
主題Scheme | Other | |||||
主題 | 医学 | |||||
出版者 | ||||||
出版者 | 弘前大学大学院医学研究科・弘前医学会 | |||||
資源タイプ | ||||||
値 | Article |